{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:52:01Z","timestamp":1790099521761,"version":"4.0.1"},"update-to":[{"DOI":"10.1016\/j.vph.2018.06.005","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000}}],"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.vph.2018.05.002","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T12:54:24Z","timestamp":1528376064000},"page":"86-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"special_numbering":"C","title":["RETRACTED: Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis"],"prefix":"10.1016","volume":"113","author":[{"given":"Amr Shaaban","family":"Hanafy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherief","family":"Abd-Elsalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed M.","family":"Dawoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2018.05.002_bb0005","first-page":"583","article-title":"Coagulation abnormalities in cirrhotic patients with portal vein thrombosis","volume":"53","author":"Amitrano","year":"2007","journal-title":"Clin. Lab."},{"key":"10.1016\/j.vph.2018.05.002_bb0010","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3748\/wjg.v12.i8.1165","article-title":"Etiology and consequences of thrombosis in abdominal vessels","volume":"12","author":"Bayraktar","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.vph.2018.05.002_bb0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-2002-33210","article-title":"Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia","volume":"34","author":"Amitrano","year":"2002","journal-title":"Endoscopy"},{"key":"10.1016\/j.vph.2018.05.002_bb0020","first-page":"2364","article-title":"Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study","volume":"96","author":"Janssen","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.vph.2018.05.002_bb0025","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1365-2036.2009.04116.x","article-title":"Review article: the modern management of portal vein thrombosis","volume":"30","author":"Chawla","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.vph.2018.05.002_bb0030","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/jhep.2000.16597","article-title":"Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy","volume":"32","author":"Condat","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.vph.2018.05.002_bb0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2036.2010.04375.x","article-title":"Ascites in patients with noncirrhotic nonmalignant extrahepatic portal vein thrombosis","volume":"32","author":"Spaander","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2018.05.002_bb0040","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/hep.22192","article-title":"Thrombosis and anticoagulation in liver disease","volume":"47","author":"Valla","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.vph.2018.05.002_bb0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2018.05.002_bb0050","first-page":"46","article-title":"Vascular liver disorders (II): portal vein thrombosis","volume":"67","author":"Hoekstra","year":"2009","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.vph.2018.05.002_bb0055","article-title":"Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups","volume":"640723","author":"G\u00f3mez-Outes","year":"2013","journal-title":"Thrombosis"},{"key":"10.1016\/j.vph.2018.05.002_bb0060","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/00007890-200005150-00006","article-title":"Changing perspectives in portal vein thrombosis and liver transplantation","volume":"15","author":"Jamieson","year":"2000","journal-title":"Transplantation"},{"issue":"14","key":"10.1016\/j.vph.2018.05.002_bb0065","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2018.05.002_bb0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2014.03.026","article-title":"Rivaroxaban post marketing risk of liver injury","volume":"61","author":"Russmann","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.vph.2018.05.002_bb0075","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2018.05.002_bb0080","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1007\/s00268-011-1198-0","article-title":"Management of acute non cirrhotic non malignant portal vein thrombosis: a systematic review","volume":"35","author":"Hall","year":"2011","journal-title":"World J. Surg."},{"key":"10.1016\/j.vph.2018.05.002_bb0085","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","article-title":"Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis","volume":"44","author":"Amitrano","year":"2010","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.vph.2018.05.002_bb0090","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic porto-systemic shunt for the management of portal vein thrombosis in cirrhosis","volume":"32","author":"Senzolo","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.vph.2018.05.002_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","article-title":"Low-molecular-weight heparin in patients with advanced cirrhosis","volume":"31","author":"Bechmann","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.vph.2018.05.002_bb0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11739-008-0219-y","article-title":"Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered","volume":"4","author":"Senzolo","year":"2009","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.vph.2018.05.002_bb0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00129689-200204000-00013","article-title":"Transhepatic thrombolysis in acute portal vein thrombosis after laparoscopic splenectomy","volume":"12","author":"Kercher","year":"2002","journal-title":"Surg. Laparosc. Endosc. Percutan. Tech."},{"key":"10.1016\/j.vph.2018.05.002_bb0110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/01.RVI.0000156265.79960.86","article-title":"Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis","volume":"16","author":"Hollingshead","year":"2005","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.vph.2018.05.002_bb0115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1160\/TH13-05-0407","article-title":"Successful treatment of acute portal vein thrombosis with rivaroxaban","volume":"110","author":"Pannach","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2018.05.002_bb0120","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1055\/s-0034-1385171","article-title":"Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban","volume":"52","author":"Lenz","year":"2014","journal-title":"Z. Gastroenterol."},{"key":"10.1016\/j.vph.2018.05.002_bb0125","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/hep.27225","article-title":"Treating thrombosis in cirrhosis patients with new oral agents: ready or not?","volume":"61","author":"Intagliata","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.vph.2018.05.002_bb0130","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.vph.2018.05.002_bb0135","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.27350","article-title":"Decreased in vitro anticoagulant potency of Rivaroxaban and apixaban in plasma from patients with cirrhosis","volume":"61","author":"Potze","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.vph.2018.05.002_bb0140","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int."}],"updated-by":[{"DOI":"10.1016\/j.vph.2023.107142","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"record-id":"43585"},{"DOI":"10.1016\/j.vph.2023.107142","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000}}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118300995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189118300995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:17:25Z","timestamp":1761527845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189118300995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"alternative-id":["S1537189118300995"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2018.05.002","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RETRACTED: Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2018.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2018.06.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}